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Figure 3. Hypothetical model of AEG1 molecular mechanisms in tumour progression and metastasis. 
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INTRODUCTION
• The epithelial-mesenchymal transition (EMT) converts epithelial cells into a mesenchymal phenotype, which is
characterized by the loss of apicobasal polarity and cell-cell junctions, cytoskeleton remodelling and acquisition of migratory
and invasive abilities.
• Having migrated to their target sites, mesenchymal cells may get their epithelial properties back through the reverse
process termed mesenchymal-epithelial transition (MET).
• These processes essentially occur during morphogenesis and have been increasingly described in tissue repair and
carcinogenesis during the last decade. Intriguingly, EMT and MET have been established as a crucial step in tumour
progression, metastatic dissemination and therapy resistance (Fig.1).
Primary research papers, case reports, theses and reviews
were identified through systematic searches in PubMed
database, mainly belonging to highly indexed journals and
published between 2006-2016. Terms such as “EMT”,
“cervical cancer”, “chemoresistance”, “metastasis”, “AEG-1”,
“MTDH”, “LYRIC” were employed. A total of 51 were
included in the final review.
METHODOLOGY
A wealth of evidence implicates AEG-1 in several signalling pathways (Fig. 3), namely:
• Ha-Ras/PI3K/Akt
• MAPK
• NF-κB
• Wnt/β-catenin
RESULTS AND DISCUSSION
CONCLUSIONS AND FUTURE APPROACHES
• EMT and MET are key players in regulating cellular plasticity in cancer, contributing to tumour progression, metastasis and
resistance to therapy inhibiting EMT represents an attractive therapeutic approach, but challenges include:
− Complexity of signalling pathways
− Block particular pathways to seek the highest effectiveness and minimal toxicity
• Cervical cancer metastasis and recurrence accounts for the majority of the related deaths and cannot be predicted due to the
lack early-stage biomarkers.
• AEG-1 has been implicated in tumour progression and chemoresistance in several malignancies, including cervical cancer.
However, a better understanding of the molecular mechanisms of the AEG-1-induced EMT still to be further elucidated.
• Yet, future research should be addressed in two main streams:
− Establishing AEG-1 as a reliable prognosis biomarker by evaluating sensitivity and specificity
− Targeting AEG-1-induced EMT to halt cervical cancer progression and chemoresistance. Possible strategies include:
o Gene silencing via RNA interference technology (siRNAs and microRNAs)
o Identifying functional domains in AEG-1 to develop novel small molecule inhibitors
o Immunotherapy (anti-AEG-1 antibodies)
GLOSSARY
MMP:Matrix metalloproteinase         NF-κB:Nuclear Factor-κ B              CDK2:Cyclin-dependent kinase 2         LHD:Lung homing domain
PI3K:Phosphotidylinositol-3-kinase     CCL20:Chemokine (C-C motif) ligand 20 LC3:Microtubule-associated protein 1A/1B-light chain 3 
AEG-1 silencing in cervical cancer cells in vitro results in:
• Reduced proliferation (Fig. 7) and increased apoptosis
• Reduced migration and invasion (Fig. 8)
• Reduced angiogenesis
Figure 1. Role of EMT in tumour progression, metastasic dissemination, therapy resistance and recurrence.   
Figure 2. FIGO staging of cervical cancer, prognosis (ie. 5-year survival rate) and stage at 
presentation. Reproduced from Longo et al. (2015) [1].
• Cervical cancer arises from the narrow end of the uterus and is the second most prevalent female cancer worldwide.
• Its progression is accurately described by the Federation of Gynecology and Obstetrics (FIGO) guidelines. Despite the
generally good prognosis at early stages, many patients are still being diagnosed at advanced stages (II-IV) where the
mortality increases as a result of metastasis and recurrence (Fig. 2).
• Cisplatin (Platinol ®) and paclitaxel (Taxol ®) constitute first-line clinical chemotherapy in metastatic or recurrent cervical
cancer. However, drug resistance limits the curative effect in some cases although the molecular mechanisms are not fully
understood.
• Astrocyte elevated gene-1 (AEG-1), also known as
metadherin (MTDH) or lysine-rich CEACAM-1-
associated protein (LYRIC), is involved in physiological
processes and has emerged in recent years as an
important contributor to EMT. This correlates with tumour
progression and chemoresistance in a variety of
cancers.
By reviewing the current literature of EMT in the
development of cervical cancer, this study aims to:
• Investigate the role of AEG-1 in tumour progression
and response to therapy
• Evaluate the suitability of AEG-1 as a potential
biomarker for cervical cancer monitoring and as a
target for new drug development
2. AEG-1 EXPRESSION IN CERVICAL CANCER AND CORRELATION WITH
CLINICOPATHOLOGICAL FEATURES
1. AEG-1 ACTS ON A PLETHORA OF SIGNALLING PATHWAYS
5. AEG-1 AND RESPONSE TO THERAPY
• CCL20 activates AEG-1 via MAPK (Erk1/2) and Akt signaling pathways and increases the
expression of mesenchymal markers vimentin, N-cadherin, and MMP2 (Fig. 6) in cervical
cancer cells in vitro.
3. AEG-1 AND EMT
4. AEG-1 IN TUMOUR PROGRESSION AND METASTASIS
Cisplatin
Paclitaxel
AEG-1 is overexpressed in cervical cancer cell lines and human tumour samples within the cell membrane
and cytoplasm, and significantly correlates with:
• FIGO staging (Fig. 4)
• Lymph node metastasis
• Overall survival (Fig. 5)
AEG-1 is suitable as an independent 
prognostic biomarker of disease 
outcome.
Figure 4. Immunohistochemical staining of AEG-1 in normal and cervical
cancer tissue at different FIGO stages (A) and quantification of results
expressed as relative OD value (B). *p<0.001. Reproduced from Zhang et al.
(2015) [2]
Figure 5. Kaplan-Meier analysis of overall
survival according to AEG-1 expression.
Reproduced from Huang et al. (2013) [3].
AEG-1 is implicated in pro-survival 
pathways
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Figure 6. Western blot analysis of AEG-1, p-Erk1/2, p-Akt, vimentin, N-
cadherin and MMP2 after increasing concentrations of CCL20 treatment
in SiHa cells. Reproduced from Zhang et al. (2015) [2]AEG-1 contributes to EMT
Figure 10. Mechanisms of AEG-1-induced chemoresistance.
AEG-1 favours stem-cell 
like properties and 
promotes tumour 
progression and metastasis
Figure 7. MTT cell proliferation assay of AEG-1
silencing in SiHa transfected cells. Reproduced from
Long et al. (2013) [4].
Figure 8. Scratch wound migration assay (A) and
transwell invasion assay (B) in HeLa transfected cells.
Reproduced from Liu et al. (2014) [5].
• AEG-1 induces:
− Protective autophagy by upregulating LC3
− Resistance to apoptosis by activating MAPK and NF-κB,
thereby inhibiting the cleavage of caspase-3
• AEG-1 has been found to mediate chemoresistance via different
mechanisms in various cancers (Fig. 10).
• AEG-1 promotes resistance to cisplatin and paclitaxel in
cervical cancer cells in vitro (Fig. 9).
Figure 9. Colony formation units (CFU) in soft agar
assay after cisplatin and paclitaxel treatment in HeLa
transfected cells. Reproduced from Liu et al. (2014) [5].
AIMS
AEG-1 confers chemoresistance 
